CC 115

Drug Profile

CC 115

Alternative Names: CC115

Latest Information Update: 19 Jul 2016

Price : $50

At a glance

  • Originator Celgene Corporation
  • Developer Celgene Corporation; Memorial Sloan-Kettering Cancer Center
  • Class Antineoplastics
  • Mechanism of Action DNA activated protein kinase inhibitors; MTOR protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Haematological malignancies; Prostate cancer; Solid tumours

Most Recent Events

  • 13 Jul 2016 Phase-I clinical trials in Prostate cancer (Combination therapy) in USA (PO) (NCT02833883)
  • 05 Oct 2015 Phase-I development is ongoing in Solid tumours and Haematological malignancies in USA and Europe
  • 30 Apr 2011 Phase-I clinical trials in Haematological malignancies (Late-stage disease, Second-line therapy or greater) in USA, France, Germany and Spain (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top